They also play a key role in identifying mood changes, visual symptoms, or signs of dehydration that should trigger prescriber review
KEY TAKEAWAYS Three major obesity organizations worked collaboratively to issue guidelines prioritizing quality of life over weight loss as primary treatment goals Guidelines explicitly address medical stigma as a structural barrier to care requiring systemic change Treatment is positioned as long-term management similar to other chronic conditions like thyroid disorders Document notably avoids calorie restriction language, focusing instead on healthy lifestyle alongside medication Setmelanotide receives strong recommendation for rare genetic obesity conditions with available genetic testing Strong medication recommendations now include GLP-1s like semaglutide and tirzepatide, plus bupropion-naltrexone combination NOTABLE QUOTE "Nobody ever asked
Manufactured and tested in California at an FDA-registered, GMP-certified facility
Novo Nordisk remains a strong and established competitor, with Wegovy continuing to perform well and its oral obesity programs showing encouraging progress
Archived from the original on 5 February 2025
In clinical trials, semaglutide has been found to be associated with significant weight loss when compared to placebo
